Androgen Receptor Targeted Treatments of Prostate Cancer

35 Years of Progress with Antiandrogens

E. David Crawford, Paul F. Schellhammer, David G. McLeod, Judd W. Moul, Celestia S. Higano, Neal Shore, Louis Denis, Peter Iversen, Mario Eisenberger, Fernand Labrie

Research output: Contribution to journalArticle

Abstract

Purpose: Antiandrogens inhibit the androgen receptor and have an important role in the treatment of prostate cancer. This review provides a historical perspective on the development and clinical benefit of antiandrogens in the treatment of prostate cancer. Materials and Methods: We searched PubMed® for clinical trials with the search terms antiandrogens and prostate cancer combined with drug names for antiandrogens. This article represents a collaboration of clinical investigators who have made critical scientific contributions leading to the approval of antiandrogens for treating patients with prostate cancer. Results: Antiandrogens differ in chemical structure and exert varying efficacy and safety profiles. The unfavorable therapeutic index of steroidal antiandrogens led to replacement by safer nonsteroidal agents. Flutamide, nilutamide and bicalutamide, which were designed to target the androgen receptor, were developed primarily for use in combination with castration to provide combined androgen blockade. Modest clinical benefits were observed with the combination of first generation antiandrogens and castration vs castration alone. With increased knowledge of androgen receptor structure and its biological functions a new generation of antiandrogens without agonist activity was designed to provide more potent inhibition of the androgen receptor. Randomized clinical trials in patients with metastatic, castration resistant prostate cancer showed significant survival benefits, which led to the approval of enzalutamide in August 2012. Apalutamide was recently approved while darolutamide is not yet approved in the United States. These next generation antiandrogens are being actively tested in earlier disease states such as nonmetastatic prostate cancer. Evolving knowledge of resistance mechanisms to androgen receptor targeted treatments will stimulate research and drug discovery for additional compounds. Further testing in nonmetastatic castration resistant prostate cancer as well as castration sensitive disease states will hopefully augment our ability to treat a broader spectrum of patients with prostate cancer. Conclusions: Antiandrogens have already provided important benefits for prostate cancer treatment. Greater knowledge about the structural and functional biology of the androgen receptor in prostate cancer will facilitate further discovery and development of further improved antiandrogens with enhanced clinical activity in patients with advanced metastatic disease. Testing these new agents earlier in the course of prostate cancer may further improve the survival and quality of life of patients with current local and/or systemic treatment modalities.

Original languageEnglish (US)
JournalJournal of Urology
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Androgen Antagonists
Androgen Receptors
Prostatic Neoplasms
Castration
Therapeutics
Flutamide
Survival
Drug Discovery
PubMed
Androgens
Names
Randomized Controlled Trials

Keywords

  • androgen
  • androgen antagonists
  • castration
  • neoplasm metastasis
  • prostatic neoplasms
  • receptors

ASJC Scopus subject areas

  • Urology

Cite this

Crawford, E. D., Schellhammer, P. F., McLeod, D. G., Moul, J. W., Higano, C. S., Shore, N., ... Labrie, F. (Accepted/In press). Androgen Receptor Targeted Treatments of Prostate Cancer: 35 Years of Progress with Antiandrogens. Journal of Urology. https://doi.org/10.1016/j.juro.2018.04.083

Androgen Receptor Targeted Treatments of Prostate Cancer : 35 Years of Progress with Antiandrogens. / Crawford, E. David; Schellhammer, Paul F.; McLeod, David G.; Moul, Judd W.; Higano, Celestia S.; Shore, Neal; Denis, Louis; Iversen, Peter; Eisenberger, Mario; Labrie, Fernand.

In: Journal of Urology, 01.01.2018.

Research output: Contribution to journalArticle

Crawford, ED, Schellhammer, PF, McLeod, DG, Moul, JW, Higano, CS, Shore, N, Denis, L, Iversen, P, Eisenberger, M & Labrie, F 2018, 'Androgen Receptor Targeted Treatments of Prostate Cancer: 35 Years of Progress with Antiandrogens', Journal of Urology. https://doi.org/10.1016/j.juro.2018.04.083
Crawford, E. David ; Schellhammer, Paul F. ; McLeod, David G. ; Moul, Judd W. ; Higano, Celestia S. ; Shore, Neal ; Denis, Louis ; Iversen, Peter ; Eisenberger, Mario ; Labrie, Fernand. / Androgen Receptor Targeted Treatments of Prostate Cancer : 35 Years of Progress with Antiandrogens. In: Journal of Urology. 2018.
@article{ca2f39adeafe471d88e0ae98fe38189d,
title = "Androgen Receptor Targeted Treatments of Prostate Cancer: 35 Years of Progress with Antiandrogens",
abstract = "Purpose: Antiandrogens inhibit the androgen receptor and have an important role in the treatment of prostate cancer. This review provides a historical perspective on the development and clinical benefit of antiandrogens in the treatment of prostate cancer. Materials and Methods: We searched PubMed{\circledR} for clinical trials with the search terms antiandrogens and prostate cancer combined with drug names for antiandrogens. This article represents a collaboration of clinical investigators who have made critical scientific contributions leading to the approval of antiandrogens for treating patients with prostate cancer. Results: Antiandrogens differ in chemical structure and exert varying efficacy and safety profiles. The unfavorable therapeutic index of steroidal antiandrogens led to replacement by safer nonsteroidal agents. Flutamide, nilutamide and bicalutamide, which were designed to target the androgen receptor, were developed primarily for use in combination with castration to provide combined androgen blockade. Modest clinical benefits were observed with the combination of first generation antiandrogens and castration vs castration alone. With increased knowledge of androgen receptor structure and its biological functions a new generation of antiandrogens without agonist activity was designed to provide more potent inhibition of the androgen receptor. Randomized clinical trials in patients with metastatic, castration resistant prostate cancer showed significant survival benefits, which led to the approval of enzalutamide in August 2012. Apalutamide was recently approved while darolutamide is not yet approved in the United States. These next generation antiandrogens are being actively tested in earlier disease states such as nonmetastatic prostate cancer. Evolving knowledge of resistance mechanisms to androgen receptor targeted treatments will stimulate research and drug discovery for additional compounds. Further testing in nonmetastatic castration resistant prostate cancer as well as castration sensitive disease states will hopefully augment our ability to treat a broader spectrum of patients with prostate cancer. Conclusions: Antiandrogens have already provided important benefits for prostate cancer treatment. Greater knowledge about the structural and functional biology of the androgen receptor in prostate cancer will facilitate further discovery and development of further improved antiandrogens with enhanced clinical activity in patients with advanced metastatic disease. Testing these new agents earlier in the course of prostate cancer may further improve the survival and quality of life of patients with current local and/or systemic treatment modalities.",
keywords = "androgen, androgen antagonists, castration, neoplasm metastasis, prostatic neoplasms, receptors",
author = "Crawford, {E. David} and Schellhammer, {Paul F.} and McLeod, {David G.} and Moul, {Judd W.} and Higano, {Celestia S.} and Neal Shore and Louis Denis and Peter Iversen and Mario Eisenberger and Fernand Labrie",
year = "2018",
month = "1",
day = "1",
doi = "10.1016/j.juro.2018.04.083",
language = "English (US)",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Androgen Receptor Targeted Treatments of Prostate Cancer

T2 - 35 Years of Progress with Antiandrogens

AU - Crawford, E. David

AU - Schellhammer, Paul F.

AU - McLeod, David G.

AU - Moul, Judd W.

AU - Higano, Celestia S.

AU - Shore, Neal

AU - Denis, Louis

AU - Iversen, Peter

AU - Eisenberger, Mario

AU - Labrie, Fernand

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Purpose: Antiandrogens inhibit the androgen receptor and have an important role in the treatment of prostate cancer. This review provides a historical perspective on the development and clinical benefit of antiandrogens in the treatment of prostate cancer. Materials and Methods: We searched PubMed® for clinical trials with the search terms antiandrogens and prostate cancer combined with drug names for antiandrogens. This article represents a collaboration of clinical investigators who have made critical scientific contributions leading to the approval of antiandrogens for treating patients with prostate cancer. Results: Antiandrogens differ in chemical structure and exert varying efficacy and safety profiles. The unfavorable therapeutic index of steroidal antiandrogens led to replacement by safer nonsteroidal agents. Flutamide, nilutamide and bicalutamide, which were designed to target the androgen receptor, were developed primarily for use in combination with castration to provide combined androgen blockade. Modest clinical benefits were observed with the combination of first generation antiandrogens and castration vs castration alone. With increased knowledge of androgen receptor structure and its biological functions a new generation of antiandrogens without agonist activity was designed to provide more potent inhibition of the androgen receptor. Randomized clinical trials in patients with metastatic, castration resistant prostate cancer showed significant survival benefits, which led to the approval of enzalutamide in August 2012. Apalutamide was recently approved while darolutamide is not yet approved in the United States. These next generation antiandrogens are being actively tested in earlier disease states such as nonmetastatic prostate cancer. Evolving knowledge of resistance mechanisms to androgen receptor targeted treatments will stimulate research and drug discovery for additional compounds. Further testing in nonmetastatic castration resistant prostate cancer as well as castration sensitive disease states will hopefully augment our ability to treat a broader spectrum of patients with prostate cancer. Conclusions: Antiandrogens have already provided important benefits for prostate cancer treatment. Greater knowledge about the structural and functional biology of the androgen receptor in prostate cancer will facilitate further discovery and development of further improved antiandrogens with enhanced clinical activity in patients with advanced metastatic disease. Testing these new agents earlier in the course of prostate cancer may further improve the survival and quality of life of patients with current local and/or systemic treatment modalities.

AB - Purpose: Antiandrogens inhibit the androgen receptor and have an important role in the treatment of prostate cancer. This review provides a historical perspective on the development and clinical benefit of antiandrogens in the treatment of prostate cancer. Materials and Methods: We searched PubMed® for clinical trials with the search terms antiandrogens and prostate cancer combined with drug names for antiandrogens. This article represents a collaboration of clinical investigators who have made critical scientific contributions leading to the approval of antiandrogens for treating patients with prostate cancer. Results: Antiandrogens differ in chemical structure and exert varying efficacy and safety profiles. The unfavorable therapeutic index of steroidal antiandrogens led to replacement by safer nonsteroidal agents. Flutamide, nilutamide and bicalutamide, which were designed to target the androgen receptor, were developed primarily for use in combination with castration to provide combined androgen blockade. Modest clinical benefits were observed with the combination of first generation antiandrogens and castration vs castration alone. With increased knowledge of androgen receptor structure and its biological functions a new generation of antiandrogens without agonist activity was designed to provide more potent inhibition of the androgen receptor. Randomized clinical trials in patients with metastatic, castration resistant prostate cancer showed significant survival benefits, which led to the approval of enzalutamide in August 2012. Apalutamide was recently approved while darolutamide is not yet approved in the United States. These next generation antiandrogens are being actively tested in earlier disease states such as nonmetastatic prostate cancer. Evolving knowledge of resistance mechanisms to androgen receptor targeted treatments will stimulate research and drug discovery for additional compounds. Further testing in nonmetastatic castration resistant prostate cancer as well as castration sensitive disease states will hopefully augment our ability to treat a broader spectrum of patients with prostate cancer. Conclusions: Antiandrogens have already provided important benefits for prostate cancer treatment. Greater knowledge about the structural and functional biology of the androgen receptor in prostate cancer will facilitate further discovery and development of further improved antiandrogens with enhanced clinical activity in patients with advanced metastatic disease. Testing these new agents earlier in the course of prostate cancer may further improve the survival and quality of life of patients with current local and/or systemic treatment modalities.

KW - androgen

KW - androgen antagonists

KW - castration

KW - neoplasm metastasis

KW - prostatic neoplasms

KW - receptors

UR - http://www.scopus.com/inward/record.url?scp=85053684058&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053684058&partnerID=8YFLogxK

U2 - 10.1016/j.juro.2018.04.083

DO - 10.1016/j.juro.2018.04.083

M3 - Article

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

ER -